贝伐单抗联合紫杉醇加卡铂一线治疗IIIB~IV期非鳞非小细胞肺癌的临床观察
| 作者: |
1孙瑜,
1陈公琰,
1王萌,
1杨芳
1 哈尔滨医科大学附属肿瘤医院肿瘤内科，哈尔滨 150040 |
| 通讯: |
陈公琰
Email: chengongyan@163.com |
摘要
目的：观察贝伐单抗联合紫杉醇加卡铂一线治疗IIIB~IV期非鳞非小细胞肺癌的临床疗效及不良反应。方法：回顾性分析哈尔滨医科大学附属肿瘤医院肿瘤内科2011年5月至2012年5月病理学确诊的IIIB~IV期非鳞非小细胞肺癌病例31例，其中12例接受贝伐单抗联合紫杉醇加卡铂方案治疗6个周期，并单药贝伐单抗进行维持治疗直至病情进展(研究组)；19例接受紫杉醇加卡铂方案治疗6个周期(对照组)，观察其疗效及不良反应，并进行随访。结果：研究组和对照组的中位无进展生存期分别为8.4个月和5.9个月(P<0.05)，中位生存期分别为17.2个月和16.6个月(P>0.05)；研究组较对照组增加的不良反应主要是高血压。结论：贝伐单抗联合紫杉醇加卡铂治疗非鳞非小细胞肺癌可延长患者的无进展生存期，且耐受性较好，具有很好的临床应用前景。
关键词：
贝伐单抗；非鳞非小细胞肺癌；紫杉醇；卡铂；不良反应
Observation of the first line treatment for patients with Stage IIIB-IV non-squamous non-small cell lung cancer by bevacizumab combined with paclitaxel and carboplatin
CorrespondingAuthor: CHEN Gongyan Email: chengongyan@163.com
Abstract
Objective: To observe clinical efficacy and safety of the first-line treatment for patients with Stage IIIB-IV non-squamous non-small cell lung cancer by bevacizumab combined with paclitaxel (PTX) and carboplatin. Methods: We retrospectively analyzed 31 patients with pathological diagnosis of Stage IIIB-IV non-squamous non-small cell lung cancer from May 2011 to May 2012. In the research group, 12 patients received bevacizumab together with PTX and carboplatin for 6 cycles, after that bevacizumab was given as maintenance treatment until progression of disease. In the control group, 19 patients received PTX and carboplatin for 6 cycles. Efficacy and safety were evaluated for both groups during treatment and follow-up. Results: Median progression-free survival was 8.4 months and 5.9 months for the research group and control group, respectively (P<0.05). Median survival was 17.2 months and 16.6 months for the research group and control group, respectively (P>0.05). Hypertension was the most frequent adverse reaction in the research group. Conclusion: Treatment of bevacizumab combined with PTX and carboplatin can extend the progression-free survival in patients with Stage IIIB-IV non-squamous non-small cell lung cancer, and is well tolerated by patients. The treatment may have good potential in clinical application in the future.